Several studies have reported the coupling of dopamine signaling to phospholipase C ␤ (PLC␤) both in vitro and in vivo. However, the precise physiological relevance of this signaling pathway in mediating dopamine behaviors is still unclear. Here we report that stimulation of dopamine receptor signaling in vivo with systemic administration of apomorphine, amphetamine, and cocaine leads to increased production of inositol triphosphate (IP 3 ) in the mouse striatum. Using selective antagonists and dopamine D 1 and D 2 receptor knock-out animals, we show that the production of IP 3 is mediated by the D 1 receptor, but not the D 2 receptor. A selective blocker of PLC␤, U73122, was used to assess the physiological relevance of D 1 -mediated IP 3 production. We show that U73122 inhibits the locomotor-stimulating effects of apomorphine, amphetamine, cocaine, and SKF81297. Furthermore, U73122 also suppresses the spontaneous hyperactivity exhibited by dopamine transporter knock-out mice. Importantly, the effects of U73122 are selective to dopamine-mediated hyperactivity, as this compound does not affect hyperactivity induced by the glutamate NMDA receptor antagonist MK801. Finally, we present evidence showing that an imbalance of D 1 -and D 2 -mediated signaling following U73122 treatment modifies the locomotor output of animals from horizontal locomotor activity to vertical activity, further highlighting the importance of the PLC␤ pathway in the regulation of forward locomotion via dopamine receptors.
Introduction
Dopamine neurotransmission regulates both motor and nonmotor behaviors (Carlsson, 2001; Beaulieu and Gainetdinov, 2011) . The role of dopamine in facilitating voluntary movement is evidenced by the locomotor-stimulant effects of dopaminergic drugs like amphetamine, and conversely by the inhibitory effects of dopamine antagonists like haloperidol (Carlsson, 2001) . Dopamine acts on the following two subclasses of receptors: the D 1 class, composed of D 1 and D 5 receptors; and the D 2 class, composed of the D 2 , D 3 , and D 4 receptors (Missale et al., 1998; Beaulieu and Gainetdinov, 2011) . Classically, the D 1 class has been shown to be positively coupled to cAMP production through a G s/olf heterotrimeric G-protein, while activation of the D 2 class leads to reduction in cAMP levels through G i/o proteins (Missale et al., 1998; Neve et al., 2004; Beaulieu and Gainetdinov, 2011) .
Traditionally, the cAMP pathway has been thought to mediate the locomotor behaviors ascribed to dopamine. However, several published studies raise the possibility that cAMP is not the only pathway for dopamine-mediated locomotion. Indeed, some dopamine-mediated locomotor behaviors are preserved when the G s /adenylyl cyclase/protein kinase A (PKA) pathway is perturbed by knocking out key signaling molecules. For example, G olf knock-out mice are hyperactive (Zhuang et al., 2000) , and basal activity is essentially normal in mice lacking the catalytic subunit of PKA or dopamine-and cAMP-regulated phosphoprotein of 32 kDa (DARPP-32; Brandon et al., 1998; Nally et al., 2003) . Alterations in the cAMP pathway are most evident in psychostimulant response, where mice deficient in DARPP-32 and G olf are less responsive to cocaine and amphetamine Zachariou et al., 2006; Corvol et al., 2007) . Furthermore, selective deletion of DARPP-32 in D 1 or D 2 neurons bidirectionally affects basal activity (Bateup et al., 2010) . These observations highlight the complexity of D 1 signaling and raise the possibility that alternate signaling pathways converge or function in parallel with cAMP signaling to elicit dopamine-mediated locomotion (Neve, 2010 ).
Several studies have described the coupling of a D 1 -like receptor to phospholipase C ␤ (PLC␤). (Undie and Friedman, 1990; Friedman et al., 1997; Undieh, 2010) . In addition, it was shown that concomitant activation of D 1 and D 2 receptors within a heterodimeric complex is linked to an increase in intracellular calcium levels (Lee et al., 2004; Rashid et al., 2007; Verma et al., 2010; Perreault et al., 2011) , likely via multiple mechanisms (Chun et al., 2013) .
Despite these studies that have convincingly demonstrated that PLC␤ is a downstream effector of dopamine signaling, the precise physiological role of this dopamine-signaling pathway remains unclear. We sought to investigate in vivo the role of dopamine receptor signaling through PLC␤ and inositol triphosphate (IP 3 ) by evaluating the contribution of this pathway to the modulation of locomotor activity. Our study shows that PLC␤ is a critical modulator of dopaminemediated forward locomotor activity, and that, in vivo, direct and indirect dopamine agonists lead to stimulation of IP 3 production via the D 1 dopamine receptor. Furthermore, the inhibition of PLC␤ signaling shifts the L-DOPAmediated locomotor activity of animals from horizontal activity to vertical activity, stressing the importance of the PLC␤ pathway for forward locomotion.
Materials and Methods
Animals. All behavioral experiments were performed during the light cycle and used 3-to 5-month-old C57BL/6J age-and sex-matched animals of either sex. Dopamine transporter knock-out (DAT-KO) mice and wild-type littermates (WT) (Giros et al., 1996) maintained on a C57BL/6J genetic background of the same age were also used. Animals were housed four to five per cage in a humidity-and temperaturecontrolled room with 12 h light/dark cycle (lights on at 8:00 A.M.). Mice were provided food and water ad libitum. All mice were experimentally naïve, and a separate group of mice was used for each testing paradigm. Experiments were conducted in accordance with the National Institutes of Health or Canadian Council for Animal Care guidelines for the care and use of animals and an approved animal protocol from either the Duke University Animal Care and Use Committee or the Faculties of Medicine and Pharmacy Animal Care Committee at the University of Toronto.
Reagents. Apomorphine, ␣-methyl-para-tyrosine (␣MPT), raclopride, SKF81297, SCH 23390, MK801, L-DOPA, carbidopa, U73122, and U73343 were purchased from Sigma-Aldrich. Anti-phospho-GluR1-Ser-845 antibody and anti-total-GluR1 antibody were purchased from Millipore. Anti-GAPDH antibody was purchased from Sigma. Species-specific Alexa Fluor 680 antibody was purchased from Invitrogen. Species-specific IRDye 800CW antibody was purchased from LI-COR Biosciences.
Drugs. Compounds or saline (0.9% NaCl) were administered intraperitoneally or subcutaneously in a volume of 10 ml/kg. For U73122 and U73343, 5 mg of compound was first dissolved in 20 l of Tween 20 and then resuspended in saline solution for intraperitoneal injection. Apomorphine was dissolved in distilled water containing 0.1% ascorbate and injected subcutaneously.
Locomotor analysis. Locomotor activity was measured in an automated infrared beam-break apparatus (AccuScan Instruments) during the light phase of the light/dark cycle. Animals were placed in an activity monitor chamber (20 ϫ 20 cm), and individual activity data were collected at 5 min intervals. Forward locomotion was measured as the total distance traveled unless otherwise indicated. Vertical activity was measured as the time spent in the vertical rearing position.
IP 3 level measurement. IP 3 measurement was performed using the GE Healthcare IP 3 [ 3 H] Biotrak Assay System (TRK1000) according to manufacturer notes. Briefly, mice were killed by cervical dislocation, and striatal tissue was dissected rapidly within 1 min. The tissue was immediately submerged in 1 ml of 10% perchloric acid and incubated for 10 min, after which the tissue was sonicated three times for 10 s. Following sonication, the sample was centrifuged for 15 min at 10,000 ϫ g at 4°C.
The supernatant was then transferred to a 15 ml conical tube and titrated to pH 7.5 using 1.5 M KOH containing 60 mM HEPES. The pH of each sample was verified to be 7.5 Ϯ 0.1. The samples were then centrifuged at 2000 ϫ g to precipitate KClO 4 . The supernatant protein concentration was measured using the Bradford assay. A protein sample in the supernatant of 100 l was then assayed using the TRK1000 kit following the procedure outlined by the manufacturer.
Western blot. Mice were pretreated with either vehicle or U73122 (10 mg/kg, i.p.) 30 min before administration of either vehicle or SKF81297 (3 mg/kg, i.p.). Fifteen minutes after the second injection, mice were killed by cervical dislocation, and striatum was rapidly dissected and snap frozen in liquid nitrogen. As described by Ghisi et al. (2009) , striatum was homogenized in 1% SDS and 2 M okadaic acid with a hand-held homogenizer, and the protein concentration determined using a BCA assay (Pierce). Fifty micrograms of striatal protein was resolved on a 10% SDS polyacrylamide gel and transferred to a PVDF membrane. The immunostaining of blots was performed overnight at 4°C with the following primary antibodies: anti-phospho-GluR1-Ser-845 (1:500) and antitotal-GluR1 (1:1500). Appropriate secondary antibodies (1:5000, Alexa Fluor 680 or IRDye 800CW) were used, and blots were developed using the LI-COR Biosciences Odyssey Imaging System. Densitometric analysis was performed with ImageJ software. Total GluR1 protein signal was used as the loading control for phospho-GluR1 protein levels.
Results

Direct and indirect dopamine agonists increase IP 3 levels in vivo
To test whether activation of dopamine receptors can lead to an activation of PLC␤ in vivo, we measured levels of IP 3 accumulation in the striatal tissue following systemic administration of direct and indirect dopamine receptor agonists. As shown in Figure 1A , the injection of mice with 1 mg/kg apomorphine, 3 mg/kg amphetamine, 20 mg/kg cocaine, or 10 mg/kg SKF81297 leads respectively to a 50, 150, 100, and 120% increase in IP 3 levels compared with saline treatment.
Based on the observation that SKF81297, a D 1 -selective agonist, increases striatal IP 3 levels, we performed a series of studies to determine whether the increase of IP 3 is due to the activation of a dopamine D 1 or D 2 receptor. Mice were injected with either SCH23390 (D 1 antagonist) or raclopride (D 2 antagonist) before injections with amphetamine (3 mg/kg). As shown in Figure 1B , injection of SCH23390 (0.1 mg/kg) completely abolishes production of IP 3 by amphetamine, while pretreatment with raclopride (2 mg/kg) has no effect on amphetamine-induced IP 3 accumulation. This indicates that stimulation of IP 3 production in the mouse striatum in vivo is mediated by D 1 and not D 2 class receptors.
To further validate the results in Figure 1B , we measured the stimulation of IP 3 accumulation after amphetamine administration (3 mg/kg) in D 1 and D 2 receptor knock-out animals (D 1 -KO and D 2 -KO). As shown in Figure 1 , C and D, the accumulation of IP 3 levels after amphetamine injection is completely abolished in D 1 -KO animals, while IP 3 accumulation is still observed in D 2 -KO mice. These results, using both pharmacological and genetic approaches, clearly demonstrate that the accumulation of IP 3 after amphetamine injection in vivo is mediated by the D 1 and not the D 2 dopamine receptor.
The PLC␤ pathway is critical for dopamine-mediated locomotor activity
Having shown that stimulation of D 1 receptors leads to an increase in striatal IP 3 levels, we next investigated the role of this pathway in dopamine-mediated locomotor activity. For this, the selective PLC␤ inhibitor U73122 was used. We first determined that U73122 effectively reduces IP 3 levels in the brain. Peripheral injection of U73122 (10 mg/kg) reduces the measureable levels of IP 3 in the striatum of both WT and DAT-KO mice, which have a fivefold increase in extracellular dopamine (Giros et al., 1996; Fig. 2) . Interestingly, DAT-KO mice show a trend decrease in their basal levels of IP 3 , and U73122 has a greater effect in reducing IP 3 levels in DAT-KO mice (Fig. 2) . These results may be explained by the 50% reduction in D 1 receptor levels in the DAT-KO mice (Giros et al., 1996; Ghisi et al., 2009 ), a compensatory adaptation to sustained hyperdopaminergia. Thus, although DAT-KO mice have high extracellular dopamine levels, signaling through the PLC␤ pathway is likely desensitized through compensatory adaptations.
We next tested whether the PLC␤/IP 3 pathway plays a role in dopamine-mediated locomotor activity. In the first set of experiments, C57BL/6J mice were pretreated with U73122 before administration of direct or indirect dopamine receptor agonists. Pretreatment with U73122 (10 mg/kg) reduces basal activity, and also reduces the locomotor responses of mice to the direct dopamine agonists apomorphine (1 mg/kg) and SKF81297 (2.5 mg/ kg), as well as to indirect dopamine agonists amphetamine (3 mg/kg) and cocaine (20 mg/kg; Fig. 3) . These results suggest a prominent role of the PLC␤/IP 3 pathway in mediating dopaminestimulated locomotor activity.
To corroborate these pharmacological results, we used a genetic model of enhanced dopamine transmission. For this, U73122 was used to reduce IP 3 levels in DAT-KO animals. DAT-KO mice have increased extracellular dopamine levels, and display hyperactivity and impaired habituation in a novel envi- ronment (Giros et al., 1996; Jones et al., 1998) . The administration of U73122 to DAT-KO mice dose dependently reduces their hyperlocomotor activity (Fig. 4) . Importantly, the injection of DAT-KO animals with U73343 (10 mg/kg), the inactive analog of U73122, has no major effect on locomotor hyperactivity, indicating that the effects of U73122 (10 mg/kg) are mediated through its inhibition of PLC␤ (Fig. 4D) .
Because D 1 receptors are known to signal through G s/olf coupling to elevate cAMP, we next performed studies to examine potential cross talk between cAMP and IP 3 pathways. One of the established indicators of D 1 -G s/olf signaling is the dopamine-mediated phosphorylation of the AMPA GluR1 subunit. Residue Ser845 is selectively phosphorylated by PKA in a dopamine-dependent manner (Roche et al., 1996; Corvol et al., 2007) . We examined whether PLC␤ inhibition would alter phosphorylation of GluR1 by comparing the levels of phospho-GluR1 after SKF81297 injection in the presence or absence of U73122. Interestingly, we discovered that U73122 pretreatment prevented the SKFinduced phosphorylation of GluR1 (Fig. 5) , suggesting the existence of some level of cross talk between the two pathways.
While U73122 administration fully inhibited locomotor responses to amphetamine, apomorphine, and SKF81297, it did not fully inhibit the effect of cocaine on locomotion at a 20 mg/kg dose (Fig. 3D) . To examine this discrepancy further, we evaluated the effect of U73122 on the locomotor activity elicited by a lower (10 mg/kg) dose of cocaine. To our surprise, while the U73122 pretreatment had a clear effect on basal activity, there was no effect on the cocaine-stimulated locomotor activity at 10 mg/kg (Fig. 6) . Furthermore, the level of activity induced by cocaine at this dose was within the same range as the response observed following the administration of 20 mg/kg cocaine along with a U73122 pretreatment. This suggests that at least two complementary mechanisms may underlie locomotor responsiveness to cocaine. It is noteworthy that previous findings have shown that DARPP-32 knock-out mice are insensitive to 10 mg/kg doses of cocaine, but respond normally to higher doses (20 mg/ kg; . Together, these observations hint that perhaps at low doses, it is the cAMP/DARPP32 pathway that mediates the locomotor-stimulating effects of cocaine (Corvol et al., 2007) , while activation of the PLC pathway would contribute to enhanced responses at higher cocaine doses.
The question of whether PLC␤ inhibition selectively affects dopamine-mediated activity was addressed using MK-801, an NMDA receptor antagonist that increases locomotor activity independent of dopamine Chartoff et al., 2005) . As shown in Figure 7A , the injection of WT mice with MK-801 (0.3 mg/kg) results in a robust increase in locomotor A)orU73122(10mg/kg;B)andtheninjectedwithvehicleorSKF81297(3mg/kg).PhosphorylatedGluR1(Ser845)andtotalGluR1protein levels in the striatum were assessed by Western blot 15 min after SKF injection. Phosphorylated GluR1 levels were corrected to total GluR1 levels and relative to vehicle in each pretreatment group. Data are presented as the mean ϮSEM. Nϭ4 -5. **pϽ0.01, Student's ttest. Figure 6 . Inhibition of PLC␤ does not affect hyperactivity induced by a low dose of cocaine (COC; 10 mg/kg). Mice were pretreated with vehicle (VEH) or U73122 (10 mg/kg). After 30 min, mice were injected with cocaine (10 mg/kg), and locomotor activity was monitored for another 60 min. Distance traveled (in centimeters) was measured over 5 min intervals, and the total distance is shown as a sum of 60 min. Data are the mean Ϯ SEM. N ϭ 8. activity that is unaffected by U73122 pretreatment (10 mg/kg). MK-801 treatment also stimulates locomotor activity in DAT-KO mice pretreated with U73122 (Fig. 7B) . These studies demonstrate that U73122 selectively inhibits dopaminemediated activity, and that the locomotor effects of the inhibitor are not due to general sedation, neuromuscular block, or muscular weakness.
Last, we evaluated the effect of the PLC␤/IP 3 pathway on the behavior elicited by dopamine itself. The previous experiments used direct or indirect agonists of the dopamine system or a genetic model of hyperdopaminergia. However, a unique feature of DAT-KO mice allows the assessment of the effect of dopamine depletion and dopamine restoration on motor activity. In DAT-KO animals, all available dopamine results from de novo synthesis by tyrosine hydroxylase (TH). Inhibition of TH by ␣MPT leads to complete depletion of the brain dopamine content in these animals, resulting in complete akinesia and immobility Costa et al., 2006; Dzirasa et al., 2006; Managò et al., 2012) . These animals are termed dopaminedeficient DAT-KO mice (DDD mice). Importantly, dopamine can be restored in DDD mice by injecting them with L-DOPA, which bypasses the inhibition of TH and restores locomotor activity. This system thus allows the assessment of dopamine signaling directly, without the use of direct or indirect ligands. We therefore investigated the functional role of the PLC␤/IP 3 pathway on dopamine motor activity using DDD mice.
DAT-KO mice were first injected with ␣MPT (250 mg/kg), and their locomotor activity was monitored for 30 min. This produced complete immobility, as expected. Mice were subsequently injected with U73122 (10 mg/kg) or vehicle. Thirty minutes after the U73122 injection, animals received an injection of L-DOPA/carbidopa (50/50 mg/kg), which normally restores locomotor activity Costa et al., 2006; Dzirasa et al., 2006; Managò et al., 2012) .
The administration of U73122 prevents the restoration of locomotor activity by L-DOPA as measured by the total distance traveled (Fig. 8A) . Interestingly, however, there is a striking switch in the locomotor behavior of the mice injected with U73122. As shown in Figure 8B , the animals that were injected with U73122 display a vertical activity phenotype after L-DOPA injection instead of horizontal activity. This result suggests that the PLC␤/IP 3 pathway is primarily important for regulating forward locomotor activity in mice, and that the inhibition of this pathway can switch the behavioral locomotor output of the dopamine system from horizontal to vertical (climbing) activity.
If so, the induction of vertical (climbing) activity in mice should be relatively insensitive to U73122 inhibition. It is well described that, at doses of 2-4 mg/kg, apomorphine induces vertical activity (climbing) in mice (Chow and Beck, 1984) . We therefore determined whether U73122 would affect apomorphine-induced climbing. As shown in Figure 8C , injection of U73122 (10 mg/kg) had no significant effect on apomorphine (3 mg/kg)-induced vertical activity, highlighting the importance of the PLC␤/IP 3 pathway in the selective modulation of horizontal locomotor activity.
Discussion
Here we report in vivo evidence that dopamine stimulation of the PLC␤/IP 3 pathway is an important contributor to locomotor activity in mice. Over the years, there have been numerous studies that have reported the ability of the dopamine system to modulate the PLC␤/IP 3 pathway; however, to date, a clear physiological role for this pathway has not been established (Undie and Friedman, 1990; . We show that blockade of this pathway leads to the inhibition of both basal and psychostimulant-mediated locomotor activity. Importantly, the PLC␤/IP 3 pathway is selective for dopaminemediated behavior, as the stimulant effects of MK-801 were not blocked by U73122 treatment.
Additionally, using a high dose of apomorphine, we demonstrate that the PLC␤/IP 3 pathway selectively modulates "forward" locomotor activity and does not inhibit vertical activity (climbing). Furthermore, in DDD mice treated with U73122, restoring locomotor activity with L-DOPA led to vertical rather than the horizontal activity. These observations clearly indicate that the PLC␤/IP 3 pathway is more important for forward locomotion than vertical activity. Intriguingly, vertical activity induced by dopamine agonists has been linked by some to L-DOPA-induced dyskinesas (Johnston et al., 2005) . Although the signaling mechanisms underlying these diverse stereotypic behaviors are poorly understood (Undie et al., 2000) , our study may provide evidence for the role of D 2 receptors in vertical activity. Alternately, our studies could be interpreted to indicate that D 1 signaling through other pathways besides PLC␤/IP 3 is responsible for dopamine-mediated vertical activity.
Evidence that G-protein-coupled dopamine receptors signal through multiple pathways has been demonstrated in several systems (Kotecha et al., 2002; Masri et al., 2008; Rajagopal et al., 2010; Chun et al., 2013) . Our studies lend support to the notion that D 1 receptors can signal through both PKA and PLC␤, and that these two pathways can exhibit cross talk in modulating Ser845, a PKA-dependent AMPA receptor phosphorylation site. In line with this, it has previously been shown that the activation of PKC, the downstream effector of PLC␤, can modulate PKA activity through a CDK5/DARPP32 signaling pathway (Bibb et al., 1999; Sahin et al., 2008) . This raises the possibility that activation of PLC␤ signaling by D 1 receptor may also contribute to the maintenance of PKA activity following its activation by this same receptor.
It has long been known that a subpopulation of D 1 -like receptors are able to stimulate IP 3 production through a PLC␤ mechanism (Undieh, 2010). These studies have been performed mainly on brain slices ex vivo. Sahu et al. (2009) showed that dopamine-induced IP 3 accumulation was attenuated in striatal slices from D 5 -KO animals. In another study, Friedman et al. (1997) were still able to detect IP 3 production following dopamine stimulation in cortical slices from D 1 -KO mice. However, it is important to note that Friedman et al. (1997) conducted IP 3 measurements on cortical slices, while our studies were performed in the striatum. Therefore, it is possible that different receptor subtypes may be mediating dopamine-induced IP 3 production in different brain structures.
In addition to reports that D 1 -like receptors mediate PLC␤/IP 3 production, a series of studies have also highlighted the ability of the D 1 /D 2 receptor heteromer to mobilize calcium through a G q /PLC␤-mediated pathway (Hasbi et al., 2009 Perreault et al., 2011) . However, a recent study reports that dopamine receptor-mediated calcium signaling can occur through multiple pathways, including those that are independent of D 1 /D 2 heteromers or G q (Chun et al., 2013) . It should also be noted that the population of medium spiny neurons coexpressing D 1 and D 2 receptors are mainly located in the nucleus accumbens , while locomotor activity is mainly regulated by the dorsal striatum (Hnasko et al., 2006) . Consequently, the modulation of the PLC␤/IP 3 pathway by dopamine receptors may be different in ventral and dorsal striatum. Thus, while activation of the D 1 /PLC␤/IP 3 pathway in the dorsal striatum may be required to modulate locomotor activity, stimulation of the PLC␤/IP 3 pathway in the ventral striatum may be required to mediate limbic responses.
In conclusion, we report the first demonstration of the involvement of a PLC␤/IP 3 pathway in selectively regulating dopamine-mediated locomotor activity. Our results show that this pathway is crucial for horizontal activity and does not influence stereotypical vertical activity displayed by mice after apomorphine injection. Interestingly, our in vivo studies indicate that direct or indirect dopamine agonists stimulate IP 3 production exclusively though D 1 dopamine receptor. This signaling cascade can potentially be targeted for the develop- Figure 8 . Vertical activity is preserved following inhibition of PLC␤. DAT-KO mice were made dopamine deficient by treatment with ␣MPT (250 mg/kg, i.p.) and were placed in locomotor activity chambers. After 30 min, mice were treated with vehicle (VEH; N ϭ 13) or U73122 (10 mg/kg, i.p.; N ϭ 16). After another 30 min, all mice were injected with a combination of L-DOPA/carbidopa (50/50 mg/kg, i.p.). A, Locomotor activity was measured as the distance traveled (in centimeters) over 5 min intervals (left). Total distance traveled in the 60 min after L-DOPA/carbidopa injection is shown in the right panel. B, During the same treatment regimen, time (in seconds) spent in vertical activity was quantified in 5 min intervals (left). The total time spent in vertical activity over the 60 min after L-DOPA/carbidopa injection is shown in the right panel. C, C57BL/6J mice were pretreated with vehicle or U73122 (10 mg/kg, i.p.) and placed in locomotor activity chambers. After 30 min, mice were injected with apomorphine (3 mg/kg, s.c.), and locomotor activity was recorded for another 60 min. The time (in seconds) spent in vertical activity is shown in 5 min intervals. N ϭ 8. All data are presented as the mean Ϯ SEM. *p Ͻ 0.05, **p Ͻ 0.01 as determined by Student's t test. ment of novel therapies for movement disorders including Parkinson's disease.
